Wnt signaling in triple negative breast cancer is associated with metastasis
Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of the disease which convey unpredictable, and poor prognosis due to limited treatment options and lack of proven effective targeted therapies.
We conducted an expression study of 240 formalin-fixed, paraffin-embedded (FFPE) primary biopsies from two cohorts, including 130 TN tumors, to identify molecular mechanisms of TN disease.
The annotation of differentially expressed genes in TN tumors contained an overrepresentation of canonical Wnt signaling components in our cohort and others. These observations were supported by upregulation of experimentally induced oncogenic Wnt/beta-catenin genes in TN tumors, recapitulated using targets induced by Wnt3A.
A functional blockade of Wnt/beta-catenin pathway by either a pharmacological Wnt-antagonist, WntC59, sulidac sulfide, or beta-catenin (functional read out of Wnt/beta-catenin pathway) SiRNA mediated genetic manipulation demonstrated that a functional perturbation of the pathway is causal to the metastasis- associated phenotypes including fibronectin-directed migration, F-actin organization, and invasion in TNBC cells. A classifier, trained on microarray data from beta-catenin transfected mammary cells, identified a disproportionate number of TNBC breast tumors as compared to other breast cancer subtypes in a meta-analysis of 11 studies and 1,878 breast cancer patients, including the two cohorts published here.
Patients identified by the Wnt/beta-catenin classifier had a greater risk of lung and brain, but not bone metastases.
These data implicate transcriptional Wnt signaling as a hallmark of TNBC disease associated with specific metastatic pathways.
Author: Nandini DeyBenjamin G BarwickCarlos S MorenoMaja Ordanic-KodaniZhengjia ChenGabriella Oprea-IliesWeining TangCharles CatzavelosKimberly F KerstannGeorge W SledgeMark AbramovitzMark BouzykPradip DeBrian R Leyland-Jones
Credits/Source: BMC Cancer
Published on: 2013-11-10
Copyright by the authors listed above - made available via BioMedCentral
(Open Access). Please
make sure to read our disclaimer
prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk
. If you wish submit your own press release, click here